Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC

ClinicalTrials.gov ID: NCT02768558

Public ClinicalTrials.gov record NCT02768558. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Patients with Stage III unresectable non-small cell lung cancer will receive thoracic radiation, cisplatin and etoposide followed by nivolumab or placebo given every 2 weeks for a year.

Study identification

NCT ID: NCT02768558
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: RTOG Foundation, Inc.; Other
Enrollment: 20 participants

Conditions and interventions

Conditions

Non-Small Cell Lung Cancer

Interventions

Radiation · Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 16, 2016
Primary completion: Jan 22, 2019
Completion: Jan 22, 2019
Last update posted: Jun 1, 2021

2016 – 2019

United States locations

U.S. sites: 16
U.S. states: 13
U.S. cities: 16

Facility	City	State	ZIP	Site status
UC San Diego Moores Cancer Center	La Jolla	California	92093	—
Stanford University	Stanford	California	94305	—
University of Florida	Gainesville	Florida	32610	—
Mount Sinai Cancer Research Center	Miami Beach	Florida	33140	—
Nancy N. & J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler Hospital	Savannah	Georgia	31405	—
University of Kentucky	Lexington	Kentucky	40536	—
Mercy Medical Cancer Center	Baltimore	Maryland	21202	—
Henry Ford Health System	Detroit	Michigan	48202	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
University of Rochester	Rochester	New York	14642	—
Metro Health Medical Center	Cleveland	Ohio	44109	—
Reading Hospital/McGlinn Cancer Institute	West Reading	Pennsylvania	19611	—
University of Texas Southwestern Medical Center	Dallas	Texas	75390	—
Inova Fairfax Hospital	Falls Church	Virginia	22042	—
Virginia Mason	Seattle	Washington	98101	—
University of Wisconsin Hospital and Clinics	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02768558, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 1, 2021 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02768558 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →